Back to Search
Start Over
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection
- Source :
- Antimicrobial Agents and Chemotherapy; July 2018, Vol. 62 Issue: 10
- Publication Year :
- 2018
-
Abstract
- Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF). However, limited data are available for its resistance profiles.
Details
- Language :
- English
- ISSN :
- 00664804 and 10986596
- Volume :
- 62
- Issue :
- 10
- Database :
- Supplemental Index
- Journal :
- Antimicrobial Agents and Chemotherapy
- Publication Type :
- Periodical
- Accession number :
- ejs46944914
- Full Text :
- https://doi.org/10.1128/AAC.01064-18